Rydar Equities’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Rydar Equities’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$34.3K	Buy	+228	New	+$36K	0.02%	217

Other funds holding XBI

Annex Advisory Services Brookfield, Wisconsin $6.11B AUM 13.75% 1-Year Est. Return

MIRAE ASSET SECURITIES (USA) INC. New York $3.57B AUM 26.78% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return

Parkway Wealth Management Plano, Texas $869M AUM 25.74% 1-Year Est. Return

Edge Wealth Management New York $666M AUM 17.64% 1-Year Est. Return

LHWM

Lake Hills Wealth Management Austin, Texas $218M AUM 31.66% 1-Year Est. Return

AIC

Ayalon Insurance Company Ramat Gan, Israel $1.2B AUM 25.57% 1-Year Est. Return

MWA

MFA Wealth Advisors Pittsburgh, Pennsylvania $589M AUM 19.71% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Rydar Equities's XBI Position: Q3 2026 in Review

Rydar Equities opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q3 2026: 228 shares worth $34.3K. The stake represents 0.02% of the portfolio and ranks #217 among its holdings.

166 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Rydar Equities held 228 shares of State Street SPDR S&P Biotech ETF worth $34.3K as of Q3 2026.
State Street SPDR S&P Biotech ETF was a new Rydar Equities position in Q3 2026.
State Street SPDR S&P Biotech ETF made up 0.02% of Rydar Equities's portfolio in Q3 2026, its #217 holding.
166 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Rydar Equities's 13F filing for Q3 2026, filed 13 Oct 2026.